Medincell's Stock Rebounds, Showing Nearly 64% Increase Since January
The biotech company from Montpellier turns positive in early afternoon, going against its decline from the previous day. This movement follows a favorable revision by a French broker, while the stock maintains a significant annual lead.
Yesterday, Portzamparc raised its price target on Medincell from €29.20 to €30.00, while reaffirming its buy rating. Based on the current price of €26.30, the new target offers a theoretical progression potential of about 14%. This revision comes after several sessions of consolidation, with the stock having lost ground at the beginning of the week after surpassing its resistance at €28.72 at the end of May. The biotech has been benefiting from a stream of positive news for several weeks, marked by the EMA's acceptance of the olanzapine LAI dossier developed with Teva, and by the announced participation in two American biotech conferences in June. The details of analyst recommendations remain a support point for the stock, in a Parisian market trending upwards (the SBF 120 is up 0.85% in session).
Technical Indicators Show Strong Mid-Term Trend
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
At €26.30, the price is above its 50-day moving average (€24.91, a difference of +5.58%) and its 200-day average (€25.39, a difference of +3.58%), a configuration that reflects the strength of the mid-term trend. The 20-day moving average at €27.11 acts as an immediate ceiling, about 3% above the current price, and remains the first milestone to cross to confirm the recovery. The RSI at 47 indicates neither overbought nor oversold conditions, which provides room for movement in both directions. The annual performance is nearly 64%, and the gain over three months reaches 17.5%, placing the stock in a positive fundamental dynamic despite recent fluctuations. The technical support identified at €22.86 remains the lower level of the current channel.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Context
Period
Period: 9M 2025
Guidance from the release
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
